Home Office data shows young Black males aged 10-17 had the highest rate of stop and search at 106.3 per 1,000 people, compared with 27.1 for their White counterparts
world2 days ago
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial.
The Phase I trial, which had 72 participants, was designed to assess the safety and tolerability of the pill, as is common in the earliest stage of clinical trials. People enrolled in the trial were either healthy, non-obese volunteers or people with type 2 diabetes.
AstraZeneca shares briefly rose as much as 2.9 per cent to a session high after the data release, before paring some gains. At 15.30 GMT they were up 0.7 per cent.
Stay up to date with the latest news. Follow KT on WhatsApp Channels.
The results from the trial gave AstraZeneca confidence to progress the drug into Phase II clinical trials, Sharon Barr, the company's executive vice president of biopharmaceuticals R&D, told a media briefing.
One of those trials of the drug, called AZD5004, will focus on reduction in body weight on average in obese and overweight participants and is expected to be completed by the end of 2025, Barr said.
When AstraZeneca announced it had licensed the experimental, once-daily obesity pill from Eccogene a year ago for up to $2 billion, it said it believed the treatment could cause fewer side effects than current injectable treatments such Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
AstraZeneca CEO Pascal Soriot acknowledged when the company announced the Eccogene deal in November 2023 that his company was "a few years behind" the roaring success of Novo Nordisk and Eli Lilly who were first to market with highly effective obesity drugs.
Barr also said data from a separate early-stage trial of 14 patients over 28 days showed that the AZD5004 pill can be taken with or without food, with no need for fasting before taking.
US biotech company Viking Therapeutics on Monday released results from an early-stage trial of its own oral obesity treatment that analysts said compared favourably to some rivals in development, leading its shares to climb 9%.
ALSO READ:
Home Office data shows young Black males aged 10-17 had the highest rate of stop and search at 106.3 per 1,000 people, compared with 27.1 for their White counterparts
world2 days ago
Palestinian Authority expresses hope that a ceasefire will bring stability to the region, especially in war-torn Gaza
world2 days ago
The ceasefire brings to a halt a war that has killed thousands in Lebanon and resulted in mass displacement on both sides of the border
world2 days ago
Since early Wednesday, traffic on the road leading to the main southern city of Sidon has been congested, as hundreds of displaced people returned to their homes following the truce
world2 days ago
Syria's state news agency reported four civilians and two soldiers were killed, and 12 people were wounded including children, women and workers in the Syrian Red Crescent
world2 days ago
Israel has acknowledged responsibility for the pager attacks in September that killed dozens of people and wounded thousand
world4 days ago
This travel-related case was associated with an ongoing outbreak of clade I mpox in central and eastern Africa, said the Public Health Agency of Canada
world5 days ago
Jordanian police had earlier cordoned off an area near the heavily policed embassy after gunshots were heard
world5 days ago